BBVA Posts Profit Beat on Higher Lending Volumes
By Elena Vardon
Banco Bilbao Vizcaya Argentaria reported better-than-expected profit and revenue for the second quarter as strong activity boosted lending volumes.
The Spanish bank made a net profit of 2.79 billion euros ($3.02 billion) for the three months ended June 30 compared with EUR2.03 billion for the same period last year, it said Wednesday.
Gross income--its top-line figure--rose to EUR9.23 billion from EUR7.19 billion. This was mainly driven by loan growth, which led to a rise in net interest income--the difference between what banks earn on loans and what they pay clients for deposits--to EUR6.48 billion from EUR5.77 billion, it said.
Analysts expected BBVA's net profit at EUR2.46 billion, gross income at EUR8.65 billion and net interest income at EUR6.45 billion, according to consensus estimates provided by the company.
The lender's common equity Tier 1 ratio--a key measure of balance-sheet strength--stood at 12.75% at the end of the quarter, against expectations of 12.84%.
"We will comfortably surpass the ambitious goals we set for ourselves for the 2021-2024 period," Chief Executive Onur Genc said.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
July 31, 2024 01:32 ET (05:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks